Types segmentation distinguishes five product formats that dominate the Chinese Materia Medica for COVID-19 market: herbal decoctions, extracts, patented formulations, single‑herb granules, and compound granules. Herbal decoctions are traditionally prepared aqueous extracts, typically prescribed in hospital settings; they represent low‑margin, high‑volume sales, contributing roughly 20 % of total revenue. Extracts, produced through solvent‑based concentration, offer standardized active‑ingredient levels and command premium pricing, accounting for about 25 % of market size. Patented formulations integrate modern pharmacokinetic enhancers with classical herbs, enabling faster regulatory clearance and higher therapeutic potency; this segment holds the largest share at approximately 30 %. Single‑herb granules, often sold over‑the‑counter, target self‑medication consumers and generate near 15 % of revenue. Compound granules combine multiple herbs in a convenient powdered form, balancing efficacy and convenience, and contribute the remaining 10 %. Collectively, these type categories shape the market taxonomy, influencing manufacturing complexity, distribution channels, and pricing dynamics across the Chinese Materia Medica for COVID-19 ecosystem.